Microbot Medical reports multiple LIBERTY account wins after full release
Microbot Medical said LIBERTY had been adopted across multiple key sales territories after full market release.
Evidence notes
- The company said new accounts included two ACCESS-PVI pivotal clinical trial sites.
- The announcement framed commercial adoption as validation of LIBERTY in everyday practice.
Company context
Microbot Medical develops LIBERTY, a compact single-use endovascular robotic system designed for remotely operated vascular access and navigation.